Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMarlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (
NASDAQPHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesRaised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs...
Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (
NASDAQPHIO), a clinical-stage biotechnology company that develops therapeutics...
Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (
NASDAQPHIO), a clinical-stage biotechnology company that develops therapeutics...
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (
NASDAQPHIO), a clinical-stage biotechnology company that develops therapeutics...
Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more insideAs 2025 kicks off, several companies are standing out as stocks to watch, driven by groundbreaking technologies, strategic market positioning, and strong growth potential. From cutting-edge oncology treatments to defense technology innovations and wellness solutions, these companies are making waves across various sectors. Here's a closer look at stocks like Phio Pharmaceuticals (
NASDAQPHIO), LightPath Technologies
NASDAQ: LPTHNASDAQLPTH)
(NASDAQ: KAVLNASDAQKAVL
, and more, making headlines and capturing investor attention. Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (
NASDAQPHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational DermatologyMarlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp. (
NASDAQPHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO), a clinical-stage biotechnology company that develops therapeutics...
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO), a clinical-stage biotechnology company that develops therapeutics...
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO) is a clinical-stage biotechnology company that develops...
Phio Pharmaceuticals Announces Publication in Frontiers in ImmunologyMarlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year AwardMarlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO),) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMarlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio...
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateMarlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO) is a clinical-stage biotechnology company exploring new...
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO) is a clinical-stage biotechnology company creating new...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMarlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO) is a clinical-stage biotechnology company creating new...
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Marlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO), a clinical stage biotechnology company whose proprietary...
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMarlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO), a clinical stage biotechnology company whose proprietary...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow SeriesMarlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO), a clinical stage biotechnology company whose proprietary...
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer ConferencePH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp....
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer CellsINTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts--(Newsfile Corp....
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesPresentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 2,...
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer ConferenceMarlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (
NASDAQPHIO), a clinical stage biotechnology company whose proprietary...
